세계의 백신 시장 : 기술 유형별, 적응증별, 최종사용자별 - 기회 분석 및 산업 예측(2024-2035년)

Vaccines Market By Technology Type, By Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035

US $ 6,090 ￦ 8,716,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 10,500 ￦ 15,027,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

백신 시장은 2023년 432억 달러로 평가되며 2024년부터 2035년까지 6.4%의 CAGR을 기록해 2035년에는 907억 달러에 달할 것으로 예상됩니다. 백신은 특정 전염병에 대한 면역력을 제공하는 생물학적 제제입니다. 백신은 일반적으로 약독화 또는 비활성화 된 병원체, 그 독소 및 표면 단백질을 함유하고 있으며, 면역 체계가 병원체를 인식하고 기억하도록 자극합니다. 백신 접종을 받으면 면역계는 항체를 생성하고 해당 병원체에 특이적인 면역 세포를 활성화하여 반응합니다. 이를 통해 체내에 방어 메커니즘이 형성되어 나중에 실제 감염성 병원체에 노출되었을 때 면역계가 신속하게 병원체를 인식하고 파괴하여 질병의 심각성을 예방하거나 완화시킬 수 있습니다. 백신은 역사적으로 많은 치명적인 질병을 제압하고 퇴치하는 데 도움을 주었으며, 현대 의학의 가장 중요한 발전 중 하나입니다.

백신 시장의 성장은 주로 인플루엔자, 폐렴구균, HPV, 기타 감염성 질환 등 성병, HPV, 기타 감염성 질환 등 백신 접종이 필요한 질환의 유병률 증가로 인해 백신 시장의 성장은 주로 발생합니다. 예를 들어, 2023년 미국 질병예방통제센터(CDC)는 3,100만 명이 독감에 걸린 것으로 추정하고 있습니다. 또한, 백신 연구개발, 제조 인프라, 공공 예방접종 프로그램에 대한 정부의 투자는 백신 시장에 큰 영향을 미칩니다. 공공-민간 파트너십, 보조금, 세제 혜택, 규제 프레임워크는 백신 개발에 인센티브를 제공하고 안전성, 유효성, 품질 기준을 보장합니다. 미국 식품의약국(FDA), 유럽의약품청(EMA), 세계보건기구(WHO)와 같은 규제 기관은 백신의 평가와 승인에 있어 매우 중요한 역할을 하며, 시장 진입과 채택에 영향을 미칩니다. 그러나 높은 개발 비용, 복잡한 제조 공정, 엄격한 규제 요건으로 인해 백신의 가격이 비싸고, 특히 중저소득 국가(LMICs)의 경우 구매 가능 가격에 한계가 있어 시장 성장을 저해할 수 있습니다. 반면, 생명공학, 유전체 과학, 면역학의 발전은 새로운 백신 개발을 통해 질병 예방과 관리를 확대할 수 있는 기회를 제공하고 있습니다. 신종 감염병, 항균제 내성 및 재유행 병원체는 미충족 의료 수요를 충족하고 공중보건 위협을 줄이기 위한 혁신적인 백신 솔루션의 필요성을 강조하고 있습니다. 백신 시장은 기술 유형, 적응증, 최종사용자, 지역별로 구분됩니다. 기술 유형별로는 재조합 및 결합 백신, 약독성 생백신, 불활성화 백신, 톡소이드 백신, 기타로 분류됩니다. 적응증별로는 폐렴구균 감염, 인플루엔자, 인유두종 바이러스, 수막염균 감염, 로타바이러스, 수두, 홍역-볼거리-풍진, 디프테리아-백일해-파상풍(DTP), 소아마비, 간염, 기타 적응증으로 나뉩니다. 최종사용자에 따라 시장은 소아, 성인, 여행자로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(일본, 중국, 호주, 인도, 한국, 기타 아시아태평양), 남미(브라질, 사우디아라비아, 아프리카, 기타 남미 지역)로 분석됩니다. 세계 백신 시장에서 사업을 전개하고 있는 주요 기업들은 Merck &Co., Inc., Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, CSL Limited, CSL Limited, Emergent Bio Solutions Inc. GlaxoSmithKline plc., Zhi Fei Biological, Bharat Biotech 등입니다. 시장에서 활동하는 주요 기업들은 제품 포트폴리오를 확장하기 위한 주요 전략으로 임상시험, 제품 출시, 제품 승인, 사업 확장을 채택하고 있습니다.

이해관계자를 위한 주요 이점

• 이 보고서는 2023년부터 2035년까지 백신 시장 분석의 시장 부문, 현재 동향, 추정 및 동향, 역학을 정량적으로 분석하여 백신 시장 분석의 시장 부문, 현재 동향, 추정 및 동향을 정량적으로 분석하여 백신 시장의 실제 기회를 밝힙니다.
• 시장 촉진요인, 시장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급업체와 공급업체의 네트워크를 강화할 수 있도록 구매자와 공급업체의 잠재력을 강조합니다.
• 백신 시장 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 수익 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 백신 시장 동향, 주요 기업, 시장 부문, 응용 분야, 시장 성장 전략에 대한 분석이 포함되어 있습니다. 기타 특전은 다음과 같습니다:
• 분기별 업데이트 및*(기업용 라이선스에만 제공됨)
• 구매 전 또는 구매 후 원하는 기업 개요 5곳을 추가하여 무료로 업데이트할 수 있습니다.
• 5 사용자 라이선스 및 엔터프라이즈 사용자 라이선스 구매 시 차기 버전을 무료로 제공합니다.
• 분석가 16시간 지원*(구매 후 보고서 검토를 통해 추가 데이터 요구사항이 발견될 경우, 질문 및 판매 후 문의사항 해결을 위해 16시간 동안 분석가의 지원을 받을 수 있음)
• 15% 무료 커스터마이징*(보고서의 조사 범위 또는 부문이 고객의 요구 사항과 일치하지 않는 경우 15%는 3 영업일 무료 작업에 해당합니다).
• 5개 사용자 라이선스 및 엔터프라이즈 사용자 라이선스 무료 데이터팩.(엑셀 버전 보고서)
• 6-12개월 이상 지난 보고서의 경우, 업데이트된 보고서를 무료로 제공함.
• 24시간 우선 대응*.
• 업계 최신 정보 및 백서 무료 제공 본 보고서의 맞춤화 가능(별도 비용 및 일정이 소요됩니다. )
• 규제 가이드라인
• 고객의 관심사에 따른 추가 기업 개요
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확장 목록
• 과거 시장 데이터
• 주요 기업의 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 백신 시장 : 기술 유형별

• 개요
• 재조합 백신 및 접합 백신
• 생 백신
• 불활화 백신
• 톡소이드 백신
• 기타

제5장 백신 시장 : 적응증별

• 개요
• 폐렴구균 감염증
• 인플루엔자
• 인유두종바이러스
• 수막염균감염증
• 로타바이러스
• 수두
• 홍역, 유행성 이하선염, 풍진
• 디프테리아, 백일해, 파상풍(DTP)
• 폴리오
• 간염
• 기타 적응증

제6장 백신 시장 : 최종사용자별

• 개요
• 소아과
• 성인
• 여행자

제7장 백신 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개사 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2023년

제9장 기업 개요

• CSL Limited
• Emergent Bio Solutions Inc.
• GlaxoSmithKline Plc.
• Merck & Co., Inc.
• Pfizer
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Bavarian Nordic
• Zhi Fei Biological
• Bharat Biotech

ksm

영문 목차

영문목차

The vaccine market was valued at $43.2 billion in 2023 and is projected to reach $90.7 billion by 2035, registering a CAGR of 6.4% from 2024 to 2035. A vaccine is a biological preparation that provides immunity to a particular infectious disease. It typically contains weakened or inactive forms of the pathogen, its toxins, or surface proteins, which stimulate the immune system to recognize and remember the pathogen. When people are vaccinated, their immune system responds by producing antibodies and activating immune cells specific to that pathogen. This creates a defense mechanism within the body, so if a person is later exposed to the actual infectious agent, the immune system can quickly recognize and destroy it, preventing or reducing the severity of the disease. Vaccines have been instrumental in controlling and eradicating many deadly diseases throughout history, making them one of the most significant advancements in modern medicine. The growth of the vaccine market is primarily driven by rise in prevalence of diseases, such as influenza, pneumococcal disease, HPV, and other infections, requiring administration of vaccines. For instance, in 2023, Centers for Disease Control and Prevention (CDC) estimated that 31 million people were sick with flu. In addition, government investment in vaccine research and development, manufacturing infrastructure, and public immunization programs significantly impacts the vaccine market. Public-private partnerships, grants, tax incentives, and regulatory frameworks incentivize vaccine development and ensure safety, efficacy, and quality standards. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), play pivotal roles in evaluating and approving vaccines for licensure, which influences market access and adoption. However, the high development costs, complex manufacturing processes, and stringent regulatory requirements contribute to the high prices of vaccines, limiting affordability, especially in low- and middle-income countries (LMICs) which may restrain the market growth. In contrast, due to ongoing advancements in biotechnology, genomics, and immunology, there is an opportunity to expand disease prevention and control through the development of new and improved vaccines. Emerging infectious diseases, antimicrobial resistance, and re-emerging pathogens underscore the need for innovative vaccine solutions to address unmet medical needs and mitigate public health threats. The vaccine market is segmented on the basis of technology type, indication, end user, and region. By technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. As per indication, the market is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP), polio, hepatitis, and other indications. Depending on end user, the market is categorized into pediatric, adults, and travelers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). Major key players that operate in the global vaccine market are Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, CSL Limited, Emergent Bio Solutions Inc., GlaxoSmithKline plc., Zhi Fei Biological, and Bharat Biotech. The key players operating in the market have adopted clinical trial, product launch, product approval, and expansion as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccines market analysis from 2023 to 2035 to identify the prevailing vaccines market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the vaccines market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global vaccines market trends, key players, market segments, application areas, and market growth strategies. Additional benefits you will get with this purchase are:
• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers. Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Technology Type

• Inactivated Vaccines
• Toxoid Vaccines
• Others
• Recombinant and Conjugate Vaccines
• Live Attenuated Vaccines

By Indication

• Pneumococcal Disease
• Influenza
• Human Papilloma Virus
• Meningococcal Disease
• Rotavirus
• Varicella
• Measles, Mumps, and Rubella
• Diphtheria, Pertussis, and Tetanus (DTP)
• Polio
• Hepatitis
• Other Indications

By End User

• Pediatric
• Adults
• Travelers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• CSL Limited
• Emergent Bi

Solutions Inc.

• GlaxoSmithKline Plc.
• Merck & Co., Inc.
• Pfizer
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Bavarian Nordic
• Zhi Fei Biological
• Bharat Biotech

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: VACCINES MARKET, BY TECHNOLOGY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Recombinant and Conjugate Vaccines
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Live Attenuated Vaccines
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Inactivated Vaccines
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Toxoid Vaccines
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Others
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: VACCINES MARKET, BY INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Pneumococcal Disease
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Influenza
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Human Papilloma Virus
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Meningococcal Disease
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Rotavirus
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country
• 5.7. Varicella
  • 5.7.1. Key market trends, growth factors and opportunities
  • 5.7.2. Market size and forecast, by region
  • 5.7.3. Market share analysis by country
• 5.8. Measles, Mumps, and Rubella
  • 5.8.1. Key market trends, growth factors and opportunities
  • 5.8.2. Market size and forecast, by region
  • 5.8.3. Market share analysis by country
• 5.9. Diphtheria, Pertussis, and Tetanus (DTP)
  • 5.9.1. Key market trends, growth factors and opportunities
  • 5.9.2. Market size and forecast, by region
  • 5.9.3. Market share analysis by country
• 5.10. Polio
  • 5.10.1. Key market trends, growth factors and opportunities
  • 5.10.2. Market size and forecast, by region
  • 5.10.3. Market share analysis by country
• 5.11. Hepatitis
  • 5.11.1. Key market trends, growth factors and opportunities
  • 5.11.2. Market size and forecast, by region
  • 5.11.3. Market share analysis by country
• 5.12. Other Indications
  • 5.12.1. Key market trends, growth factors and opportunities
  • 5.12.2. Market size and forecast, by region
  • 5.12.3. Market share analysis by country

CHAPTER 6: VACCINES MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Pediatric
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Adults
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Travelers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: VACCINES MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Technology Type
  • 7.2.3. Market size and forecast, by Indication
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Technology Type
    • 7.2.5.1.2. Market size and forecast, by Indication
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Technology Type
    • 7.2.5.2.2. Market size and forecast, by Indication
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Technology Type
    • 7.2.5.3.2. Market size and forecast, by Indication
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Technology Type
  • 7.3.3. Market size and forecast, by Indication
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Technology Type
    • 7.3.5.1.2. Market size and forecast, by Indication
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.3.2. Market size and forecast, by Indication
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Technology Type
    • 7.3.5.4.2. Market size and forecast, by Indication
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Technology Type
    • 7.3.5.5.2. Market size and forecast, by Indication
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Technology Type
    • 7.3.5.6.2. Market size and forecast, by Indication
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Technology Type
  • 7.4.3. Market size and forecast, by Indication
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Technology Type
    • 7.4.5.1.2. Market size and forecast, by Indication
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Technology Type
    • 7.4.5.2.2. Market size and forecast, by Indication
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Technology Type
    • 7.4.5.3.2. Market size and forecast, by Indication
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Technology Type
    • 7.4.5.4.2. Market size and forecast, by Indication
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Technology Type
    • 7.4.5.5.2. Market size and forecast, by Indication
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Technology Type
    • 7.4.5.6.2. Market size and forecast, by Indication
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Technology Type
  • 7.5.3. Market size and forecast, by Indication
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Technology Type
    • 7.5.5.1.2. Market size and forecast, by Indication
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Technology Type
    • 7.5.5.2.2. Market size and forecast, by Indication
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Technology Type
    • 7.5.5.3.2. Market size and forecast, by Indication
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Technology Type
    • 7.5.5.4.2. Market size and forecast, by Indication
    • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. CSL Limited
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Emergent Bio Solutions Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. GlaxoSmithKline Plc.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Merck & Co., Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Pfizer
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Sanofi
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Serum Institute of India Pvt. Ltd.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Bavarian Nordic
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Zhi Fei Biological
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Bharat Biotech
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료